Clinics

Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application

Volumn 1, Issue , 2008, Pages 51-110

  Pérez Egea, Rosario ^a   Pérez, Victor ^a   Puigdemont, Dolors ^a   Álvarez, Enric ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Affective disorders; Clinical aspects; Depressive disorders; Epidemiology; Physiopathology

Indexed keywords

EID: 84889628232     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619337.ch2     Document Type: Chapter

References (117)

1. Akiskal HS. Dysthymia as a temperamental variant of affective disorder. Eur Psychiatry. 1996, 11:117S-122S.
2. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition. 2000, 16:544-546.
3. American Psychiatric Association. DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Publishing; Washington, DC, 2000, pp 1-943.
4. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001, 62:448-452.
5. Artigas F. Neurotransmisión aminérgica y su modulación por fármacos antidepresivos. In: Roca M, ed. Médica Panamericana S.A., Madrid, 1999.
6. Ayuso Mateos JL, Ayuso Gutiérrez JL. Uso clínico de los fármacos antidepresivos. In: Vázquez-Barquero JL, ed. Psiquiatría en atención primaria. Grupo Aula Médica, Madrid, 1998.
7. Álamo C, Cuenca E, López-Muñoz F. Neurotransmisión noradrenérgica en el sistema nervioso central. In: Vallejo C, Cuenca E, eds. Depresión y noradrenalina. Ed.Doyma, Barcelona, 1999, pp 1-15.
8. Álvarez E. Utilización de fármacos antidepresivos y "activación". Temas clave en el manejo de la depresión. Edimsa, Madrid, 1998.
9. Álvarez E, Pérez-Solá V, Pérez-Blanco J. Tratamiento de la depresión resistente. In: Roca M, ed. Trastornos del humor. Médica Panamericana S.A., Madrid, 1999.
10. Álvarez P. Deprivación del sueño. Psiquiatría Biológica. 1997, 4:50-54.
11. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999, 19:427-434.
12. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995, 15:49-57.
13. Bouckoms AJ. The role of stereotactic cingulotomy in the treatment of intractable depression. In: Amsterdam JD, ed. Refractory Depression. Raven Press, New York, 1991, pp 233-242.
14. Boyd J, Weissman MM. Epidemiology. Handbook of affective disorders. Churchill Livingstone, London, 1982, pp 109-125.
15. Brasseur R. A multicentre open trial of fluoxetine in depressed out-patients in Belgium. Int Clin Psychopharmacol. 1989, 4 Suppl 1:107-111.
16. Brown GW, Harris TO, Hepworth C. Life events and endogenous depression. A puzzle reexamined. Arch Gen Psychiatry. 1994, 51:525-534.
17. Carney MW, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of E.C.T. response. Br J Psychiatry. 1965, 111:659-674.
18. Carrasco JL. Empleo de fármacos antidepresivos en el paciente con patologías médicas. In: Roca M, Bernardo M, eds. Trastornos depresivos en patologías médicas. Masson, Barcelona, 1996.
19. Clayton PJ, Halikas JA, Maurice WL. The depression of widowhood. Br J Psychiatry. 1972, 120:71-77.
20. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet. 1963, 1:79-81.
21. Coppen A, Prange AJ, Jr., Whybrow PC, Noguera R. Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry. 1972, 26:474-478.
22. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000, 60:121-130.
23. Crespo JM. Depresión mayor. In: Roca M, ed. Trastornos del humor. Médica Panamericana, Madrid, 1999.
24. Cuenca E, Cuenca-Söderberg O. Fluvoxamina. Aspectos farmacológicos y clínicos. An Psiquiatría. 1990.
25. Cuenca E. Interacciones farmacológicas de los agentes antidepresivos y citocromo P-450. Temas clave en el manejo de la depresión. Edimsa, Madrid, 1998, pp 13-25.
26. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997, 7 Suppl 1:S23-S35.
27. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997, 54:597-606.
28. Ereshefsky L, Riesenman C, Lam YW. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry. 1996, 57 Suppl 8:17-24.
29. Fava M, Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom. 1994, 62:160-167.
30. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997, 154:1760-1762.
31. Feighner JP, Robins E, Guze SB, Woodruff RA, Jr., Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972, 26:57-63.
32. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry. 1994, 55 Suppl A: 62-68.
33. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001, 103:66-72.
34. Frank JD. Persuasion and healing. A comparative study of psychotherapy. 2nd ed. Johns Hopkins University Press; Baltimore, 1973, pp 1-378.
35. Gastó C, Vieta E. Trastornos afectivos. In: Cervilla J, Gracía-Ribera C, eds. Fundamentos biológicos en psiquiatría. Masson, Barcelona, 2000.
36. Gastó P. Antidepresivos en los trastornos de personalidad. In: Vallejo J, Gastó C, eds. Antidepresivos en la clínica psiquiátrica. Mosby-Doyma, Barcelona, 1996, pp 79-89.
37. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000, 283:3082-3088.
38. Gibert J, Moreno M, Ignacio J. Antidepresivos. In: Roca M, ed. Trastornos del humor. Médica Panamericana, Madrid, 1999, pp 793-812.
39. Gibert J, Rojas M, Micó J. Neurotransmisión peptidérgica y depresión. In: Roca M, ed. Médica Panamericana, Madrid, 1999.
40. Goodnick PJ. Predictores de la respuesta al tratamiento en trastornos del estado de ánimo. Predictores Biológicos. Edika Med, Barcelona, 1997, pp 187-193.
41. Gorman JM, Kent JM. SSRIs and SMRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry. 1999, 60 Suppl 4:33-38.
42. Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatr Scand Suppl. 2000, 30-35.
43. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23:56-62.
44. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967, 6:278-296.
45. Herrán A, Núñez MJ, Vázquez-Barquero JL. Trastornos del estado de ánimo. In: Vázquez-Barquero JL, ed. Psiquiatría en Atención Primaria. Grupo Aula Médica, Madrid, 1998.
46. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997, 277:333-340.
47. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol. 1997, 16:14-17.
48. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995, 49:280-294.
49. Howland RH. Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol. 1991, 11:83-92.
50. Invernizzi G, Mauri MC, Waintraub L. Antidepressant efficacy in the treatment of dysthymia. Eur Neuropsychopharmacol. 1997, 7 Suppl 3:S329-S336.
51. Janowsky DS, el Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972, 2:632-635.
52. Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999, 56:431-437.
53. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993, 50:387-393.
54. Kaplan HJ, Sadock BJ. Sinopsis de psiquiatría. 8th ed. Panamericana; Madrid, 1999.
55. Kendell RE, Gourlay J. The clinical distinction between psychotic and neurotic depressions. Br J Psychiatry. 1970, 117:257-260.
56. Kessler RC, McGonagle KA, Nelson CB, Hughes M, Swartz M, Blazer DG. Sex and depression in the National Comorbidity Survey. II: Cohort effects. J Affect Disord. 1994, 30:15-26.
57. Klein DF, Davis JM. The drug treatment of depression. JAMA. 1970, 212:1962-1963.
58. Kroessler D. Relative Efficacy Rates for Therapies of Delusional Depression. Convuls Ther. 1985, 1:173-182.
59. Lapierre YD. Pharmacological therapy of dysthymia. Acta Psychiatr Scand Suppl. 1994, 383:42-48.
60. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. 1999, 45:270-273.
61. Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. J Clin Psychiatry. 1991, 52:336-337.
62. Lewis A. Melancholia: a clincial survey of depressive states. J Ment Sci. 1934, 80:277-378.
63. Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995, 33:67-74.
64. Lin EH, Katon WJ, Simon GE, Von Korff M, Bush TM, Rutter CM, Saunders KW, Walker EA. Achieving guidelines for the treatment of depression in primary care: is physician education enough? Med Care. 1997, 35:831-842.
65. López-Ibor Aliño JJ. In: Roca M, ed. Trastornos del humor. Médica Panamericana, Madrid, 1999.
66. Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM, Nahas Z, Lisanby SH. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002, 51:280-287.
67. Markowitz JC. Psychotherapy of dysthymia. Am J Psychiatry. 1994, 151:1114-1121.
68. Martin JL, Barbanoj MJ, Schlaepfer TE, Clos S, Perez V, Kulisevsky J, Gironell A. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev. 2002, 2, CD003493.
69. Medhus A, Heskestad S, Thue JF. [A combination effect of mianserin (Tolvon) and tricyclic antidepressive agents. Improved antidepressive therapy]. Tidsskr Nor Laegeforen. 1990, 110:3527-3528.
70. a ed. Médica Panamericana, Madrid, 1998.
71. Menchón JM, Vallejo J. Distimia. In: Roca M, ed. Trastornos del humor. Médica Panamericana, Madrid, 1999, pp 409-443.
72. Mezzich JE, Fabrega H, Jr., Coffman GA. Multiaxial characterization of depressive patients. J Nerv Ment Dis. 1987, 175:339-346.
73. Montes MR, Gurpegui M. Neuroquímica psiquiátrica. In: Cervilla J, García-Ribera C, eds. Fundamentos biológicos en psiquiatría. Masson, Barcelona, 2000.
74. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995, 10 Suppl 4:37-45.
75. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997, 58:437-439.
76. Murphy BE, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol. 1991, 11:121-126.
77. Murphy JM, Monson RR, Laird NM, Sobol AM, Leighton AH. A comparison of diagnostic interviews for depression in the Stirling County study: challenges for psychiatric epidemiology. Arch Gen Psychiatry. 2000, 57:230-236.
78. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996, 153:311-320.
79. Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm. 1999, 106:795-798.
80. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994, 14:419-423.
81. O'Dwyer AM, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995, 33:123-128.
82. Pacheco L, Malo P, Aragüés E. Síndrome de discontinuación con los ISRS. Aplicaciones prácticas a la clínica diaria. Temas clave en el manejo de la depresión. Edimsa, Madrid, 1998.
83. Paddin JJ, Martínez E, Arias F. Fenómenos de abstinencia tras la discontinuación del tratamiento con los inhibidores de recaptación de serotonina. Psiquiatría Biológica. 1997, 4:162-166.
84. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebocontrolled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry. 1999, 56:375-379.
85. Pérez-Solá V, Álvarez E, Pérez-Blanco J. Fármacos antidepresivos. In: Cervilla J, García-Ribera C, eds. Fundamentos biológocos en psiquiatría. Masson, Barcelona, 2000, pp 315-325.
86. aed. Grupo Aula Médica, Madrid, 1998.
87. Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003, 160:105-111.
88. Preskorn, S. Tratamiento ambulatorio de la depresión. Professional Communications, 1994.
89. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology (Berl). 1987, 92:431-437.
90. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl). 1977, 53:309-314.
91. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry. 1994, 55 Suppl A:34-39.
92. Rudolph R, Entsuah R, Derivan A. Early clinical response in depression to venlafaxine hydrochloride. Biol Psychiatry. 1991, 29:630S.
93. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK, Jr., Goodman R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000, 47:276-286.
94. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965, 122:509-522.
95. Servei Català de Salut, Brugulat P, Casaus P, Fernández de Sanmamed, MJ, Foz, G, Mercader, M, Molina C, Palao D, Pastor C, Pérez Arnau F, Pérez Simó R, Saenz I. Recomanacions per a l'atenció als problemes de salut mental més freqüents en l'atenció primària de salut. Servei Català deSalut. Barcelona, 2000.
96. Smith M, Weissman MM. Epidemiology. In: Paykel ES, ed. Handbook of the Affective Disorders. Churchill Livingstone, Edinburgh, 1992, pp 111-129.
97. Souery D, Mendlewicz J. Compliance and therapeutic issues in resistant depression. Int Clin Psychopharmacol. 1998, 13 Suppl 2:S13-S18.
98. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978, 35:773-782.
99. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988, 2:850-851.
100. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology. 1993, 43:211-213.
101. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999, 156:2017.
102. Thase ME, Friedman ES, Howland RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry. 2001, 62 Suppl 18:18-24.
103. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002, 63:95-103.
104. Theobald DE, Kasper M, Nick-Kresl CA, Rader M, Passik SD. Documentation of indicators for antidepressant treatment and response in an HMO primary care population. J Managed Care. 2000, 6:494-498.
105. Vallejo J, Menchón JM. Tratamiento de las depresiones no melancólicas. In: Vallejo J, Gastó C, eds. Antidepresivos en la clínica psiquiátrica. Mosby-Doyma, Madrid, 1996.
106. aed. Editorial Médica JIMS, Barcelona, 1999.
107. Vallejo J. Teorías bioquímicas clásicas de la depresión. In: Vallejo J, Cuenca E, eds. Depresión y noradrenalina. Doyma, Barcelona, 1999.
108. aed. Masson, Barcelona, 2000, pp 261-288.
109. aed. Masson, Barcelona, 2000, pp 308-327.
110. aed. Masson, Barcelona, 2000, pp 192-216.
111. Vázquez-Barquero JL. Epidemiología de los trastornos del humor. In: Roca M, ed. Trastornos del humor. Médica Panamericana, Madrid, 1999.
112. Warrington SJ. Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1992, 7 Suppl 2:13-19.
113. Wing JK, Cooper JE, Sartorius N. The measurement and classification of psychiatric symptoms. Cambridge University Press; Cambridge, 1974.
114. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med. 999, 61:698-711.
115. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999, 156:646-649.
116. World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization; Geneva, 1993.
117. Zohar J, Kaplan Z, Amsterdam JD. Reserpine augmentation in resistant depression: a review. In: Amsterdam JD, ed. Refractory Depression. Raven Press, New York, 1991, pp 219-222.